JP2018518167A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518167A5
JP2018518167A5 JP2017562026A JP2017562026A JP2018518167A5 JP 2018518167 A5 JP2018518167 A5 JP 2018518167A5 JP 2017562026 A JP2017562026 A JP 2017562026A JP 2017562026 A JP2017562026 A JP 2017562026A JP 2018518167 A5 JP2018518167 A5 JP 2018518167A5
Authority
JP
Japan
Prior art keywords
seq
sequence
human type
composition
vii collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017562026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518167A (ja
JP6873052B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/035326 external-priority patent/WO2016196670A1/en
Publication of JP2018518167A publication Critical patent/JP2018518167A/ja
Publication of JP2018518167A5 publication Critical patent/JP2018518167A5/ja
Priority to JP2021070962A priority Critical patent/JP2021130660A/ja
Application granted granted Critical
Publication of JP6873052B2 publication Critical patent/JP6873052B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017562026A 2015-06-01 2016-06-01 Ｖｉｉ型コラーゲンにおけるアンチセンス誘導エクソン排除 Active JP6873052B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021070962A JP2021130660A (ja) 2015-06-01 2021-04-20 Ｖｉｉ型コラーゲンにおけるアンチセンス誘導エクソン排除

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169454P 2015-06-01 2015-06-01
US62/169,454 2015-06-01
PCT/US2016/035326 WO2016196670A1 (en) 2015-06-01 2016-06-01 Antisense-induced exon exclusion in type vii collagen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021070962A Division JP2021130660A (ja) 2015-06-01 2021-04-20 Ｖｉｉ型コラーゲンにおけるアンチセンス誘導エクソン排除

Publications (3)

Publication Number Publication Date
JP2018518167A JP2018518167A (ja) 2018-07-12
JP2018518167A5 true JP2018518167A5 (enExample) 2019-07-04
JP6873052B2 JP6873052B2 (ja) 2021-05-19

Family

ID=57441924

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017562026A Active JP6873052B2 (ja) 2015-06-01 2016-06-01 Ｖｉｉ型コラーゲンにおけるアンチセンス誘導エクソン排除
JP2021070962A Pending JP2021130660A (ja) 2015-06-01 2021-04-20 Ｖｉｉ型コラーゲンにおけるアンチセンス誘導エクソン排除

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021070962A Pending JP2021130660A (ja) 2015-06-01 2021-04-20 Ｖｉｉ型コラーゲンにおけるアンチセンス誘導エクソン排除

Country Status (6)

Country Link
US (3) US10849917B2 (enExample)
EP (2) EP3302497A4 (enExample)
JP (2) JP6873052B2 (enExample)
HK (1) HK1253335A1 (enExample)
MA (1) MA50829A (enExample)
WO (1) WO2016196670A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504124D0 (en) 2015-03-11 2015-04-22 Proqr Therapeutics B V Oligonucleotides
AU2016265457B2 (en) * 2015-05-21 2022-06-09 Wings Therapeutics, Inc. Antisense oligonucleotides to treat dystrophic epidermolysis bullosa
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
AU2017385962B2 (en) * 2016-12-30 2021-09-02 Olipass Corporation Exon skipping by peptide nucleic acid derivatives

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
WO1986005519A1 (en) 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5843738A (en) * 1990-08-14 1998-12-01 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
PT876165E (pt) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp Composicoes de polimeros reticulados e processos para a sua utilizacao
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
WO2000061810A1 (en) 1999-04-08 2000-10-19 Oasis Biosciences, Inc. Antisense oligonucleotides comprising universal and/or degenerate bases
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US20030125276A1 (en) * 2001-11-08 2003-07-03 Isis Pharmaceuticals Inc. Antisense modulation of thyroid hormone receptor interactor 6 expression
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
WO2003020739A2 (en) 2001-09-04 2003-03-13 Exiqon A/S Novel lna compositions and uses thereof
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
KR20030084444A (ko) 2002-04-26 2003-11-01 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003291682A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US7211668B2 (en) 2003-07-28 2007-05-01 Panagene, Inc. PNA monomer and precursor
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
PL1794174T3 (pl) 2004-09-01 2012-11-30 Dynavax Tech Corp Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
DE202005008426U1 (de) 2005-05-31 2005-09-15 Ricon Sieb Und Foerdertechnik Fördervorrichtung mit Fördertuch
US7534819B2 (en) * 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
ES2397113T3 (es) 2005-06-23 2013-03-04 Isis Pharmaceuticals, Inc. Composiciones y procedimientos para modular el corte y empalme de SMN2
ES2645410T3 (es) 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
US7935816B2 (en) 2007-10-25 2011-05-03 Gene Tools, Llc Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
DK2207779T3 (da) 2007-11-15 2014-07-14 Sarepta Therapeutics Inc Fremgangsmåde til syntese af morpholinooligomerer
AU2008345033B2 (en) * 2007-12-28 2014-04-03 Sarepta Therapeutics, Inc. Immunomodulatory agents and methods of use
JP2012523225A (ja) 2009-04-10 2012-10-04 アソシアシオン・アンスティテュ・ドゥ・ミオロジー 疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法
US20120149757A1 (en) 2009-04-13 2012-06-14 Krainer Adrian R Compositions and methods for modulation of smn2 splicing
JP5944311B2 (ja) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
CN115227709A (zh) 2009-06-17 2022-10-25 冷泉港实验室 用于在对象中调节smn2剪接的组合物和方法
WO2011005942A2 (en) 2009-07-08 2011-01-13 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
US7868657B1 (en) 2009-07-22 2011-01-11 Qualcomm, Incorporated High voltage logic circuits
US7995708B2 (en) 2009-08-14 2011-08-09 Varian Medical Systems, Inc. X-ray tube bearing shaft and hub
US8802642B2 (en) 2010-04-28 2014-08-12 Iowa State University Research Foundation, Inc. Spinal muscular atrophy treatment via targeting SMN2 catalytic core
KR102182663B1 (ko) 2010-05-28 2020-11-25 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
DK2623507T3 (da) 2010-09-30 2017-01-02 Nippon Shinyaku Co Ltd Morpholinonukleinsyrederivat
IL273838B (en) 2011-05-05 2022-09-01 Sarepta Therapeutics Inc Peptide and oligonucleotide conjugates, preparations containing them and their uses
ES2867054T3 (es) * 2011-10-11 2021-10-20 Inst Nat Sante Rech Med Tratamiento de salto de exones para epidermólisis ampollosa distrófica
EP2581448B1 (en) 2011-10-13 2015-01-28 Association Institut de Myologie Tricyclo-phosphorothioate DNA
EP2776450B1 (en) * 2011-11-10 2018-04-04 Shire Human Genetic Therapies, Inc. Antisense oligonucleotide modulators of serotonin receptor 2c and uses thereof
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス， インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
WO2013086441A2 (en) * 2011-12-08 2013-06-13 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
GB201202561D0 (en) * 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
EP2754714A1 (en) 2013-01-14 2014-07-16 Sarepta Therapeutics, Inc. Inhibitory oligonucleotides and their use in therapy
CN106459915A (zh) 2014-02-04 2017-02-22 凯德药业公司 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物
GB201504124D0 (en) * 2015-03-11 2015-04-22 Proqr Therapeutics B V Oligonucleotides
AU2016265457B2 (en) * 2015-05-21 2022-06-09 Wings Therapeutics, Inc. Antisense oligonucleotides to treat dystrophic epidermolysis bullosa
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
WO2019079637A2 (en) 2017-10-18 2019-04-25 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERIC COMPOUNDS
US10867398B2 (en) 2017-11-21 2020-12-15 Reliance Core Consulting LLC Methods, systems, apparatuses and devices for facilitating motion analysis in an environment

Similar Documents

Publication Publication Date Title
JP7041879B2 (ja) アンチセンス核酸
JP6977998B2 (ja) アンチセンス核酸
JP2018530560A5 (enExample)
KR102335801B1 (ko) 안티센스 핵산
CN106795197B (zh) 改性寡核苷酸及其制备方法
JP2021533804A5 (enExample)
KR102522059B1 (ko) 안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
JP6542662B2 (ja) オリゴヌクレオチドアナログのボロン酸結合体
JP2016502858A5 (enExample)
JP2016533761A5 (enExample)
CN103154245A (zh) 反义核酸
JP2021090458A5 (enExample)
JP2018525015A5 (enExample)
CN104321334A (zh) 三环核苷及由其制备的低聚化合物
CA2996164A1 (en) Modified antisense oligomers for exon inclusion in spinal muscular atrophy
CN118109469A (zh) 诱导外显子50的跳读的反义核酸
CA3173049A1 (en) Antisense nucleic acid inducing skipping of exon 51
TWI726914B (zh) 肌萎縮症治療用反義核酸
JP2020521491A5 (enExample)
CN114127286A (zh) 用于调节选择性内含子的剪接的方法和组合物
TW202325846A (zh) 用於治療周邊髓鞘蛋白22相關疾病的嗎啉代寡聚物
HK1231920A1 (en) Antisense nucleic acid